Format

Send to

Choose Destination
J Infect Dis. 2010 Jan 1;201(1):52-61. doi: 10.1086/648478.

Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy.

Author information

1
Faculty of Biotechnology, University of Naples Federico II, Naples, Italy.

Abstract

BACKGROUND:

The most serious criticisms leveled at bacteriophage therapy are as follows: phages induce neutralizing antibodies, phages are active only when administered shortly after bacterial infection, and phage-resistant bacteria emerge rapidly in the course of therapy.

METHODS:

Phages lytic for several Salmonella enterica serovars were isolated by means of standard protocols from feces of patients with gastroenteritis. Growth of S. enterica serovar Paratyphi B (Salp572(phi1S)) in the presence of phage phi1 (selected from among 8 phages for its larger host range) provided a phage phi1-resistant bacterial strain (Salp572(phi1R)). The properties of the Salp572(phi1S) and Salp572(phi1R) strains and of phage phi1 were studied in a mouse model of experimental infection.

RESULTS:

Phages induced nonneutralizing antibodies and were active 2 weeks after experimental infection of mice; phage-resistant bacteria were avirulent and short lived in vivo. More importantly, phage-resistant bacteria were excellent vaccines, protecting against lethal doses of heterologous S. enterica serovars.

CONCLUSIONS:

Phage therapy effectiveness has not yet been properly assessed.

PMID:
19929381
DOI:
10.1086/648478
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center